Aciclovir is a guanosine analogue antiviral drug, marketed under trade names such as Cyclovir, Herpex, Acivir,Acivirax, Zovirax and Zovir (GSK). One of the most commonly-used antiviral drugs, it is primarily used for the treatment of herpes simplex virus infections, as well as in the treatment of herpes zoster (shingles).
Philip Chapper & Company Ltd, a UK company with over 40 years’ experience within medical supplies, is to showcase innovative products from new suppliers at the industry’s largest European trade fair.
Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has renegotiated the terms of its commercial partnership with Meda for Xerese, its unique marketed product for cold sores (herpes labialis).
Medivir AB, a research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has signed an agreement with Daewoong Pharmaceutical Co. Ltd. to exclusively distribute Medivir's unique cold sore treatment Xerclear in China and Hong Kong.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company's commercialization partner, Meda AB, has launched Medivir's unique cold sore treatment Xerese in the United States.
China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.
Medivir and Meda today announced an agreement for the commercialization of Medivir’s cold sore product which will be marketed in North America under the trade name Xerese™.
Treating genital herpes does not reduce the risk of HIV, according to a study published on Friday in the journal Lancet, the AP/Newsweek reports (Cheng, AP/Newsweek, 6/19). Herpes simplex virus-2 has been shown to increase the risk of HIV by as much as threefold, so the researchers examined whether treating HSV-2 might reduce the risk of HIV, Bloomberg reports.
The silicone vaginal ring steadily releases aciclovir: a treatment for genital herpes. It is known that women with genital herpes are at increased risk of HIV infection because the genital blisters caused by the infection increase the transmissibility of sexually acquired HIV.